Cltc | 64-72-2

• 物质功能分类: 原料药 - 抗生素类药物 - 四环素类药
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 四环素类
• 英文名称: Cltc
• 英文别名: 7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
• CAS: 64-72-2
• 化学式: C₂₂H₂₃ClN₂O₈
• 分子量: 478.89
• InChiKey: CYDMQBQPVICBEU-UHFFFAOYSA-N

物化性质

• 熔点：
  210-215 °C (dec.)(lit.)
• 比旋光度：
  D23 -240°
• 溶解度：
  1 M NaOH：可溶50mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  0.44
• 重原子数：
  33.0
• 可旋转键数：
  2.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  181.62
• 氢给体数：
  6.0
• 氢受体数：
  9.0

安全信息

• 危险等级：
  3
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  2
• 海关编码：
  29413020
• 危险品运输编号：
  NONH for all modes of transport
• 危险类别：
  6.1
• RTECS号：
  QI7800000
• 包装等级：
  II
• 储存条件：
  密封、干燥、避光保存。

SDS

Name:	Chlortetracycline Hydrochloride can be used as Secondary Standard Material Safety Data Sheet
Synonym:	CTC; 7-Chlorotetracycline . HC
CAS:	64-72-2

Section 1 - Chemical Product MSDS Name:Chlortetracycline Hydrochloride can be used as Secondary Standard Material Safety Data Sheet
Synonym:CTC; 7-Chlorotetracycline . HC

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
64-72-2	Chlortetracycline Hydrochloride	99+	200-591-7

Hazard Symbols: XN
Risk Phrases: 63

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Possible risk of harm to the unborn child.Moisture sensitive.Light sensitive.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
Adverse reproductive effects have been reported in animals.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Do NOT get water inside containers. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation. Do not get water inside containers.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Store protected from light. Use only in a chemical fume hood. Keep from contact with moist air and steam.
Storage:
Do not store in direct sunlight. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep refrigerated. (Store below 4C/39F.) Store protected from moisture.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 64-72-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Odorless.
pH: 2.8 @ 0.5% solution
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 220 deg C dec
Autoignition Temperature: Not available.
Flash Point: 210 deg C ( 410.00 deg F)
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature: 210 deg C
Solubility in water: 8.6 MG/ML (28C)
Specific Gravity/Density:
Molecular Formula: C22H23ClN2O8.HCl
Molecular Weight: 515.33

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, light, dust generation, exposure to air, exposure to moist air or water.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 64-72-2: QI7800000 LD50/LC50:
CAS# 64-72-2: Oral, mouse: LD50 = 2314 mg/kg.
Carcinogenicity:
Chlortetracycline Hydrochloride - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 63 Possible risk of harm to the unborn child.
Safety Phrases:
S 28A After contact with skin, wash immediately with
plenty of water.
S 36/37 Wear suitable protective clothing and
gloves.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 64-72-2: No information available.
Canada
CAS# 64-72-2 is listed on Canada's DSL List.
CAS# 64-72-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 64-72-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

Chlortetracycline HCl（7-氯四环素）是首批确定的四环素类抗生素之一。

体外研究

Chlortetracycline HCl是从放线菌属（Streptomyces aureofaciens）中获得的一种广谱抗菌剂。它能够强力结合到30S亚基的一个位点，从而抑制多种革兰氏阳性和革兰氏阴性菌的活性，包括专性厌氧菌在内。Chlortetracycline HCl主要通过抑制核糖体水平上的蛋白质合成来抑制细菌生长。其对以下几种菌株具有抗菌作用：Streptococcus pyogenes、Diplococcus pneumoniae、Bacillus subtilis、Streptococcus faecalis 和 Mycobacterium ranae，对应的最小抑菌浓度（MIC）分别为0.292 mg/L、0.098 mg/L、0.195 mg/L、0.3 mg/L和0.15 mg/L。

用途

Chlortetracycline HCl是一种广谱抗生素，对革兰氏阳性和阴性菌均有抗菌作用。此外，它还可用作细胞渗透荧光探针，用于测量内质网中的钙离子流。

反应信息

• 作为反应物：
  描述：

  Cltc 在 phosphate buffer 作用下， 反应 13.0h， 生成 Lumichlorotetracycline
  参考文献：
  名称：

  Organic photochemistry. 92. Formation and characterization of lumitetracycline-type photoproducts from members of the tetracycline family

  摘要：

  DOI：

  10.1021/jo00016a030

文献信息

• Substituted Tetracycline Compounds
  申请人：Kim Oak K.

  公开号：US20100305072A1

  公开（公告）日：2010-12-02

  The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.

  本发明至少部分涉及新型替代四环素化合物。这些四环素化合物可用于治疗许多对四环素化合物敏感的疾病状态，如细菌感染和肿瘤。
• Compositions and methods for treating hemorrhagic virus infections and other disorders
  申请人：——

  公开号：US20020077276A1

  公开（公告）日：2002-06-20

  Cytokine-receptor and cytokine antagonist-enriched blood-dervided compositions and methods of preparing and using the compositions are provided. Also provided are compositions and methods for the treatment or prevention of disorders, especially acute inflammatory disorders involving pathological responses of the immune system, such as viral hemorrhagic diseases, sepsis, rheumatoid arthritis and other autoimmune disorders, acute cardiovascular events, flare-ups and acute phases of multiple sclerosis, wasting disorders and other disorders involving deleterious expression of cytokines and other factors, including tumor necrosis factor (TNF) and interleukin-1 (IL-1) are provided.

  提供了富含细胞因子受体和细胞因子拮抗剂的血液衍生物组合物的制备和使用方法。还提供了用于治疗或预防疾病的组合物和方法，特别是涉及免疫系统病理反应的急性炎症性疾病，如病毒性出血热疾病、败血症、类风湿关节炎和其他自身免疫性疾病、急性心血管事件、多发性硬化的急性阶段、消耗性疾病和其他涉及细胞因子和其他因子有害表达的疾病，包括肿瘤坏死因子（TNF）和白细胞介素-1（IL-1）。
• TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES
  申请人：Paratek Pharmaceuticals, Inc.

  公开号：US20180016225A1

  公开（公告）日：2018-01-18

  Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described.

  使用具有目标治疗活性的四环素化合物治疗疾病的方法和化合物被描述。
• METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA
  申请人：Paratek Pharmaceuticals, Inc.

  公开号：US20150321997A1

  公开（公告）日：2015-11-12

  A method for modulating RNA with tetracycline compounds is described.

  描述了一种用四环素化合物调节RNA的方法。
• 7-phenyl-substituted tetracycline compounds
  申请人：Nelson L. Mark

  公开号：US20070155708A1

  公开（公告）日：2007-07-05

  7-phenyl-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described.

  本文介绍了7-苯基取代四环素化合物、治疗对四环素敏感状态的方法以及含有7-苯基取代四环素化合物的制药组合物。